Advances in nanocarriers as drug delivery systems in Chagas disease

References

• Echeverria LE, Morillo CA. American trypanosomiasis (Chagas disease). Infect Dis Clin. 2019;33(1):119–134. doi:10.1016/j.idc.2018.10.015
   PubMed Web of Science ®Google Scholar
• Andrade DV, Gollob KJ, Dutra WO. Acute Chagas disease: new global challenges for an old neglected disease. PLoS Negl Trop Dis. 2014;8(7):e3010. doi:10.1371/journal.pntd.000301025077613
   PubMedGoogle Scholar
• Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357(10):1018–1027. doi:10.1056/NEJMra06414217804846
   PubMed Web of Science ®Google Scholar
• Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1(2):92–100. doi:10.1016/S1473-3099(01)00065-211871482
   PubMedGoogle Scholar
• Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. doi:10.1016/S0140-6736(17)31612-428673423
   PubMed Web of Science ®Google Scholar
• Sánchez-Valdéz FJ, Pérez Brandán C, Ferreira A, Basombrío MÁ. Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease. Expert Rev Vaccines. 2015;14(5):681–697. doi:10.1586/14760584.2015.98998925496192
   PubMed Web of Science ®Google Scholar
• Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today. 2000;3(5):163–171. doi:10.1016/S1461-5347(00)00255-810785658
   PubMedGoogle Scholar
• Damhorst GL, Murtagh M, Rodriguez WR, Bashir R. Microfluidics and nanotechnology for detection of global infectious diseases. Proc IEEE. 2015;103(2):150–160. doi:10.1109/JPROC.2014.2385078
   Web of Science ®Google Scholar
• Galvin P, Thompson D, Ryan KB, et al. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell Mol Life Sci. 2012;69(3):389–404. doi:10.1007/s00018-011-0856-622015612
   PubMedGoogle Scholar
• Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci. 2010;31(5):199–205. doi:10.1016/j.tips.2010.01.00320172613
   PubMedGoogle Scholar
• Seigneuric R, Markey L, Nuyten DS, et al. From nanotechnology to nanomedicine: applications to cancer research. Curr Mol Med. 2010;10(7):640–652.20712588
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther. 2010;128(2):324–335. doi:10.1016/j.pharmthera.2010.07.00720705093
   PubMedGoogle Scholar
• Dellian M, Yuan F, Trubetskoy V, Torchilin V, Jain R. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer. 2000;82(9):1513.10789717
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666. doi:10.1016/j.biomaterials.2010.01.06520138662
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan J, Mahmoud EA, Kim G, Morachis JM, Almutairi A. Multiresponse strategies to modulate burst degradation and release from nanoparticles. ACS Nano. 2010;4(10):5930–5936. doi:10.1021/nn100968e20828178
   PubMed Web of Science ®Google Scholar
• Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater. 2009;8(7):543. doi:10.1038/nmat244219525947
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Miranda OR, Moyano DF, et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011;6(9):e24374. doi:10.1371/journal.pone.002437421931696
   PubMed Web of Science ®Google Scholar
• Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci. 2008;105(33):11613–11618. doi:10.1073/pnas.080176310518697944
   PubMed Web of Science ®Google Scholar
• Miller CR, Bondurant B, McLean SD, McGovern KA, O’Brien DF. Liposome− cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry. 1998;37(37):12875–12883. doi:10.1021/bi980096y9737866
   PubMed Web of Science ®Google Scholar
• Osaka T, Nakanishi T, Shanmugam S, Takahama S, Zhang H. Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells. Colloids Surf B Biointerfaces. 2009;71(2):325–330. doi:10.1016/j.colsurfb.2009.03.00419361963
   PubMed Web of Science ®Google Scholar
• Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364(2):272–280. doi:10.1016/j.ijpharm.2008.04.03618555624
   PubMed Web of Science ®Google Scholar
• Serda RE, Gu J, Bhavane RC, et al. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials. 2009;30(13):2440–2448. doi:10.1016/j.biomaterials.2009.01.01919215978
   PubMed Web of Science ®Google Scholar
• Valente I, Celasco E, Marchisio D, Barresi A. Nanoprecipitation in confined impinging jets mixers: production, characterization and scale-up of pegylated nanospheres and nanocapsules for pharmaceutical use. Chem Eng Sci. 2012;77:217–227. doi:10.1016/j.ces.2012.02.050
   Web of Science ®Google Scholar
• Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine. 2015;10:1001–1018. doi:10.2147/IJN.S5693225678788
   PubMed Web of Science ®Google Scholar
• Hans M, Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid St Mate Sci. 2002;6(4):319–327. doi:10.1016/S1359-0286(02)00117-1
   Web of Science ®Google Scholar
• Hu X, Zou G. Biodegradable polymeric nanoparticles as drug delivery systems. Amino Acids Biotic Resour. 2003;2(1–2):1–20.
   Google Scholar
• Gonzalez-Martin G, Merino I, Rodriguez-Cabezas MN, Torres M, Nunez R, Osuna A. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. J Pharm Pharmacol. 1998;50(1):29–35.9580223
   PubMed Web of Science ®Google Scholar
• Müller RH, Lherm C, Herbert J, Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials. 1990;11(8):590–595.2279061
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin G, Figueroa C, Merino I, Osuna A. Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur J Pharm Biopharm. 2000;49(2):137–142.10704896
   PubMed Web of Science ®Google Scholar
• Molina J, Urbina J, Gref R, Brener Z, Rodriguez JM. Cure of experimental Chagas’ disease by the bis-triazole DO870 incorporated into ‘stealth’ polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother. 2001;47(1):101–104. doi:10.1093/jac/47.1.10111152439
   PubMedGoogle Scholar
• GFP DS, Yokoyama-Yasunaka JK, Seabra AB, Miguel DC, de Oliveira MG, Uliana SRB. Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis. Nitric Oxide. 2006;15(3):209–216. doi:10.1016/j.niox.2006.01.01116527502
   PubMedGoogle Scholar
• Gil-Jaramillo N, Motta FN, Favali CB, Bastos I, Santana JM. Dendritic cells: a double-edged sword in immune responses during Chagas disease. Front Microbiol. 2016;7:1076. doi:10.3389/fmicb.2016.0107627471496
   PubMed Web of Science ®Google Scholar
• Gutierrez FR, Mineo TW, Pavanelli WR, Guedes PM, Silva JS. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz. 2009;104(2):236–245. doi:10.1590/s0074-0276200900090003019753479
   PubMedGoogle Scholar
• Seabra AB, Da Silva R, De Souza GF, De Oliveira MG. Antithrombogenic Polynitrosated Polyester/Poly (methyl methacrylate) blend for the coating of blood‐contacting surfaces. Artif Organs. 2008;32(4):262–267. doi:10.1111/j.1525-1594.2008.00540.x18370938
   PubMedGoogle Scholar
• Amadeu TP, Seabra AB, De Oliveira MG, Costa AM. S‐nitrosoglutathione‐containing hydrogel accelerates rat cutaneous wound repair. J Eur Acad Dermatol Venereol. 2007;21(5):629–637. doi:10.1111/j.1468-3083.2006.02032.x17447976
   PubMedGoogle Scholar
• Seabra AB, Kitice NA, Pelegrino MT, et al. Nitric oxide-releasing polymeric nanoparticles against Trypanosoma cruzi. J Phys: Conf Ser 2015;617:012020. doi:10.1088/1742-6596/617/1/012020
   Google Scholar
• Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15(21–22):958–965. doi:10.1016/j.drudis.2010.08.00720727418
   PubMed Web of Science ®Google Scholar
• Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’drug delivery systems. Eur J Pharm Sci. 2000;11(2):S93–S98.11033431
   PubMed Web of Science ®Google Scholar
• Sposito PA, Mazzeti AL, Faria CD, et al. Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity. Int J Nanomedicine. 2017;12:3785–3799. doi:10.2147/IJN.S13370828553114
   PubMed Web of Science ®Google Scholar
• Branquinho RT, Mosqueira VCF, JCV DO-S, Simoes-Silva MR, Saude-Guimaraes DA, de Lana M. Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease. Antimicrob Agents Chemother. 2014;58(4):2067–2075. doi:10.1128/AAC.00617-1324449777
   PubMedGoogle Scholar
• Abriata JP, Eloy JO, Riul TB, Campos PM, Baruffi MD, Marchetti JM. Poly-epsilon-caprolactone nanoparticles enhance ursolic acid in vivo efficacy against Trypanosoma cruzi infection. Mater Sci Eng C Mater Biol Appl. 2017;77:1196–1203. doi:10.1016/j.msec.2017.03.26628531996
   PubMedGoogle Scholar
• Rial MS, Scalise ML, Arrua EC, Esteva MI, Salomon CJ, Fichera LE. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. PLoS Negl Trop Dis. 2017;11(12):e0006119. doi:10.1371/journal.pntd.000611929267280
   PubMedGoogle Scholar
• Tessarolo LD, Mello CP, Lima DB, et al. Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to Trypanosoma cruzi. Parasitology. 2018;145(9):1–8. doi:10.1017/S003118201700185829144211
   PubMedGoogle Scholar
• Fujiwara M, Shiokawa K, Morigaki K, Zhu Y, Nakahara Y. Calcium carbonate microcapsules encapsulating biomacromolecules. Chem Eng J. 2008;137(1):14–22. doi:10.1016/j.cej.2007.09.010
   Web of Science ®Google Scholar
• Seremeta KP, Arrúa EC, Okulik NB, Salomon CJ. Development and characterization of benznidazole nano-and microparticles: a new tool for pediatric treatment of Chagas disease? Colloids Surf B Biointerfaces. 2019;177:169–177. doi:10.1016/j.colsurfb.2019.01.03930731393
   PubMedGoogle Scholar
• Huang SL. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1167–1176. doi:10.1016/j.addr.2008.03.00318479776
   PubMed Web of Science ®Google Scholar
• Crommelin DJ, Schreier H. Liposomes In: Kreuter J, editor. Colloidal Drug Delivery Systems. Boca Raton: CRC Press; 2014:85–159.
   Google Scholar
• Mody N, Tekade RK, Mehra NK, Chopdey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS PharmSciTech. 2014;15(2):388–399. doi:10.1208/s12249-014-0073-324431104
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4(4):297–305.17979650
   PubMedGoogle Scholar
• Morilla MJ, Montanari JA, Prieto MJ, Lopez MO, Petray PB, Romero EL. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. Int J Pharm. 2004;278(2):311–318. doi:10.1016/j.ijpharm.2004.03.02515196636
   PubMedGoogle Scholar
• Soto CDA, Mirkin GA, Solana ME, Cappa SMG. Trypanosoma cruzi infection modulates in vivo expression of major histocompatibility complex class II molecules on antigen-presenting cells and T-cell stimulatory activity of dendritic cells in a strain-dependent manner. Infect Immun. 2003;71(3):1194–1199. doi:10.1128/iai.71.3.1194-1199.200312595432
   PubMedGoogle Scholar
• Morilla MJ, Montanari J, Frank F, et al. Etanidazole in pH-sensitive liposomes: design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. J Control Release. 2005;103(3):599–607. doi:10.1016/j.jconrel.2004.12.01215820407
   PubMed Web of Science ®Google Scholar
• Espada R, Valdespina S, Alfonso C, Rivas G, Ballesteros MP, Torrado JJ. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int J Pharm. 2008;361(1–2):64–69. doi:10.1016/j.ijpharm.2008.05.01318599228
   PubMedGoogle Scholar
• Torrado J, Espada R, Ballesteros M, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci. 2008;97(7):2405–2425. doi:10.1002/jps.2117917893903
   PubMed Web of Science ®Google Scholar
• Actor P, Wind S, Pagano J. Potentiation of amphotericin B activity against trypanosoma congolense in mice. Proc Soc Exp Biol Med. 1962;110(3):409–412. doi:10.3181/00379727-110-2753213859221
   PubMedGoogle Scholar
• Rolon M, Seco EM, Vega C, et al. Selective activity of polyene macrolides produced by genetically modified Streptomyces on Trypanosoma cruzi. Int J Antimicrob Agents. 2006;28(2):104–109. doi:10.1016/j.ijantimicag.2006.02.02516844353
   PubMedGoogle Scholar
• Yardley V, Croft SL. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg. 1999;61(2):193–197. doi:10.4269/ajtmh.1999.61.19310463666
   PubMed Web of Science ®Google Scholar
• Torrado JJ, Serrano DR, Uchegbu IF. The oral delivery of amphotericin B. Ther Deliv. 2013;4(1):9–12.23401912
   PubMedGoogle Scholar
• Cencig S, Coltel N, Truyens C, Carlier Y. Parasitic loads in tissues of mice infected with trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis. 2011;5(6):e1216. doi:10.1371/journal.pntd.000137021738811
   PubMedGoogle Scholar
• Tarleton R. Trypanosoma cruzi and Chagas disease: cause and effect. In: Tyler KM, Miles MA, editors. American Trypanosomiasis. World Class Parasites, vol 7 Boston: Springer; 2003:107–115.
   Google Scholar
• Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010;28(4):181–188. doi:10.1016/j.tibtech.2009.12.00720079548
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64(2–3):83–101. doi:10.1016/j.addr.2012.09.021
   Web of Science ®Google Scholar
• Müller RH, MaÈder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.10840199
   PubMed Web of Science ®Google Scholar
• Tomiotto-Pellissier F, Miranda-Sapla MM, Machado LF, et al. Nanotechnology as a potential therapeutic alternative for schistosomiasis. Acta Trop. 2017;174:64–71. doi:10.1016/j.actatropica.2017.06.02528668252
   PubMedGoogle Scholar
• Wissing S, Kayser O, Müller R. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–1272. doi:10.1016/j.addr.2003.12.00215109768
   PubMed Web of Science ®Google Scholar
• Muller RH. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 1995;41(1):62–69.
   Web of Science ®Google Scholar
• Carneiro ZA, Maia PID, Sesti-Costa R, et al. In vitro and in vivo trypanocidal activity of H(2)bdtc-loaded solid lipid nanoparticles. PLoS Negl Trop Dis. 2014;8(5):e2847. doi:10.1371/journal.pntd.000284724810753
   PubMedGoogle Scholar
• Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308(5958):457. doi:10.1038/308457a06709052
   PubMed Web of Science ®Google Scholar
• Wilson NS, Duewell P, Yang B, et al. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J Immunol. 2014;192(7):3259–3268. doi:10.4049/jimmunol.130201124610009
   PubMed Web of Science ®Google Scholar
• Lendemans DG, Egert AM, Hook S, Rades T. Cage-like complexes formed by DOTAP, Quil-A and cholesterol. Int J Pharm. 2007;332(1–2):192–195. doi:10.1016/j.ijpharm.2006.09.02917049770
   PubMedGoogle Scholar
• Friede M, Hermand P, inventors; SmithKline Beechman Biologicals s.a., assignee. Vaccine Adjuvants. United States patent 6558670. 2003 May 6.
   Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine. 2009;27(33):4388–4401. doi:10.1016/j.vaccine.2009.05.03219450632
   PubMed Web of Science ®Google Scholar
• Cruz-Bustos T, Gonzalez-Gonzalez G, Morales-Sanfrutos J, Megia-Fernandez A, Santoyo-Gonzalez F, Osuna A. Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy. Int J Nanomedicine. 2012;7(2):5941–5956. doi:10.2147/IJN.S3555623233802
   PubMedGoogle Scholar
• Nhavene EPF, Da Silva WM, Junior RRT, et al. Chitosan grafted into mesoporous silica nanoparticles as benznidazol carrier for Chagas diseases treatment. Microporous Mesoporous Mater. 2018;272:265–275. doi:10.1016/j.micromeso.2018.06.035
   Web of Science ®Google Scholar
• Eger I, Soares MJ. Endocytosis in Trypanosoma cruzi (Euglenozoa: kinetoplastea) epimastigotes: visualization of ingested transferrin-gold nanoparticle complexes by confocal laser microscopy. J Microbiol Methods. 2012;91(1):101–105. doi:10.1016/j.mimet.2012.07.01322820201
   PubMedGoogle Scholar
• Ho CC, Luo YH, Chuang TH, Yang CS, Ling YC, Lin P. Quantum dots induced monocyte chemotactic protein-1 expression via MyD88-dependent Toll-like receptor signaling pathways in macrophages. Toxicology. 2013;308:1–9. doi:10.1016/j.tox.2013.03.00323499856
   PubMed Web of Science ®Google Scholar
• Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WC. In vivo quantum-dot toxicity assessment. Small. 2010;6(1):138–144. doi:10.1002/smll.20090062619743433
   PubMed Web of Science ®Google Scholar
• Wu T, Tang M. Toxicity of quantum dots on respiratory system. Inhal Toxicol. 2014;26(2):128–139. doi:10.3109/08958378.2013.87176224495248
   PubMed Web of Science ®Google Scholar
• Chen N, He Y, Su Y, et al. The cytotoxicity of cadmium-based quantum dots. Biomaterials. 2012;33(5):1238–1244. doi:10.1016/j.biomaterials.2011.10.07022078811
   PubMed Web of Science ®Google Scholar
• Nagy A, Hollingsworth JA, Hu B, et al. Functionalization-dependent induction of cellular survival pathways by CdSe quantum dots in primary normal human bronchial epithelial cells. ACS Nano. 2013;7(10):8397–8411. doi:10.1021/nn305532k24007210
   PubMedGoogle Scholar
• Stahl CV, Almeida DB, de Thomaz AA, et al. Studying nanotoxic effects of CdTe Quantum Dots in Trypanosoma cruzi Colloidal Quantum Dots for Biomedical Applications V. Proc. SPIE 7575, Colloidal Quantum Dots for Biomedical Applications V, 757513; February 17; 2010; San Francisco, CA.
   Google Scholar
• de Araujo SC, de Mattos AC, Teixeira HF, Coelho PM, Nelson DL, de Oliveira MC. Improvement of in vitro efficacy of a novel schistosomicidal drug by incorporation into nanoemulsions. Int J Pharm. 2007;337(1–2):307–315. doi:10.1016/j.ijpharm.2007.01.00917292573
   PubMedGoogle Scholar
• Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv. 2005;2(4):297–310.16305433
   PubMedGoogle Scholar
• Jaiswal M, Dudhe R, Sharma P. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123–127. doi:10.1007/s13205-014-0214-0
   PubMedGoogle Scholar
• Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol. 2011;2(05):626. doi:10.4236/jbnb.2011.225075
   Google Scholar
• de Oliveira ECV, Carneiro ZA, de Albuquerque S, Marchetti JM. Development and evaluation of a nanoemulsion containing ursolic acid: a promising trypanocidal agent. AAPS PharmSciTech. 2017;18(7):2551–2560. doi:10.1208/s12249-017-0736-y28224391
   PubMedGoogle Scholar
• Vermelho AB, Cardoso VD, Ricci E, Dos Santos EP, Supuran CT. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J Enzyme Inhib Med Chem. 2017;33(1):139–146. doi:10.1080/14756366.2017.1405264
   Web of Science ®Google Scholar
• Streck L, Sarmento VH, de Menezes RP, Fernandes-Pedrosa MF, Martins AM, da Silva-Júnior AA. Tailoring microstructural, drug release properties, and antichagasic efficacy of biocompatible oil-in-water benznidazol-loaded nanoemulsions. Int J Pharm. 2019;555:36–48. doi:10.1016/j.ijpharm.2018.11.04130448310
   PubMedGoogle Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1. doi:10.1007/s11095-007-9271-y17109211
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Poly SA. Poly (ethylene oxide)–poly (propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm. 2007;66(3):303–317. doi:10.1016/j.ejpb.2007.03.02217481869
   PubMed Web of Science ®Google Scholar
• Attia ABE, Ong ZY, Hedrick JL, et al. Mixed micelles self-assembled from block copolymers for drug delivery. Curr Opin Colloid Interface Sci. 2011;16(3):182–194. doi:10.1016/j.cocis.2010.10.003
   Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815. doi:10.1038/nnano.2011.16622020122
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab. 2009;10(8):836–841.20214578
   PubMed Web of Science ®Google Scholar
• Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev. 2012;64(2–3):237–245. doi:10.1016/j.addr.2012.09.016
   Google Scholar
• Rolon M, Serrano DR, Lalatsa A, et al. Engineering oral and parenteral amorphous amphotericin B formulations against experimental trypanosoma cruzi infections. Mol Pharm. 2017;14(4):1095–1106. doi:10.1021/acs.molpharmaceut.6b0103428198632
   PubMedGoogle Scholar
• Huang L, Wei G, Sun X, et al. A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy. Eur J Med Chem. 2018;151:294–303. doi:10.1016/j.ejmech.2018.03.07729627724
   PubMedGoogle Scholar
• Mai B, Gao Y, Li M, et al. Photodynamic antimicrobial chemotherapy for Staphylococcus aureus and multidrug-resistant bacterial burn infection in vitro and in vivo. Int J Nanomedicine. 2017;12:5915. doi:10.2147/IJN.S13818528860757
   PubMedGoogle Scholar
• Yuan Y, Liu Z-Q, Jin H, et al. Photodynamic antimicrobial chemotherapy with the novel amino acid-porphyrin conjugate 4I: in vitro and in vivo studies. PLoS One. 2017;12(5):e0176529. doi:10.1371/journal.pone.017652928493985
   PubMedGoogle Scholar
• de Morais FAP, Enumo A, Gonçalves RS, et al. Hypericin photodynamic activity. Part III: in vitro evaluation in different nanocarriers against trypomastigotes of trypanosoma cruzi. Photochem Photobiol Sci. 2019;18(2):487–494. doi:10.1039/C8PP00444G30534717
   PubMedGoogle Scholar
• Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn. 2003;3(2):153–161. doi:10.1586/14737159.3.2.15312647993
   PubMed Web of Science ®Google Scholar
• Singh RP, Oh BK, Choi JW. Application of peptide nucleic acid towards development of nanobiosensor arrays. Bioelectrochemistry. 2010;79(2):153–161. doi:10.1016/j.bioelechem.2010.02.00420356802
   PubMed Web of Science ®Google Scholar
• Patolsky F, Zheng G, Lieber CM. Nanowire-based Biosensors. Anal Chem. 2006;78(13):4260–4269.
   Google Scholar
• Pereira SV, Bertolino FA, Fernandez-Baldo MA, et al. A microfluidic device based on a screen-printed carbon electrode with electrodeposited gold nanoparticles for the detection of IgG anti-Trypanosoma cruzi antibodies. Analyst. 2011;136(22):4745–4751. doi:10.1039/c1an15569e21984978
   PubMedGoogle Scholar
• Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, et al. Use of a novel Chagas urine nanoparticle test (Chunap) for diagnosis of congenital Chagas disease. PLoS Negl Trop Dis. 2014;8(10):e3211. doi:10.1371/journal.pntd.000321125275534
   PubMed Web of Science ®Google Scholar
• Janissen R, Sahoo PK, Santos CA, et al. InP nanowire biosensor with tailored biofunctionalization: ultrasensitive and highly selective disease biomarker detection. Nano Lett. 2017;17(10):5938–5949. doi:10.1021/acs.nanolett.7b0180328895736
   PubMedGoogle Scholar
• Vaculovicova M, Michalek P, Krizkova S, Macka M, Adam V. Nanotechnology-based analytical approaches for detection of viruses. Anal Methods. 2017;9(16):2375–2391. doi:10.1039/C7AY00048K
   Web of Science ®Google Scholar
• M-I R-G, L-J V-G, Beyssen D, Sarry F, Reyna M-A, Ibarra-Cerdeña C-N. Biosensors to diagnose chagas disease: a brief review. Sensors. 2017;17(11):2629. doi:10.3390/s17050968
   PubMed Web of Science ®Google Scholar
• Araújo AF, de Alencar BC, Vasconcelos JRC, et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun. 2005;73(9):6017–6025. doi:10.1128/IAI.73.9.6017-6025.200516113322
   PubMed Web of Science ®Google Scholar
• de Alencar BC, Araújo AF, Penido ML, Gazzinelli RT, Rodrigues MM. Cross-priming of long lived protective CD8+ T cells against Trypanosoma cruzi infection: importance of a TLR9 agonist and CD4+ T cells. Vaccine. 2007;25(32):6018–6027. doi:10.1016/j.vaccine.2007.05.02217629597
   PubMed Web of Science ®Google Scholar
• Hoft DF, Schnapp AR, Eickhoff CS, Roodman ST. Involvement of CD4+ Th1 cells in systemic immunity protective against primary and secondary challenges with trypanosoma cruzi. Infect Immun. 2000;68(1):197–204. doi:10.1128/iai.68.1.197-204.200010603388
   PubMedGoogle Scholar
• Low HP, Santos MA, Wizel B, Tarleton RL. Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL. J Immunol. 1998;160(4):1817–1823.9469442
   PubMed Web of Science ®Google Scholar
• Miller MJ, Wrightsman RA, Manning JE. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response. Exp Parasitol. 1996;84(2):156–167. doi:10.1006/expr.1996.01018932765
   PubMedGoogle Scholar
• Tarleton R. Depletion of CD8+ T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with trypanosoma cruzi. J Immunol. 1990;144(2):717–724.2104903
   PubMed Web of Science ®Google Scholar
• Tarleton RL, Sun J, Zhang L, Postan M. Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas’ disease. Infect Immun. 1994;62(5):1820–1829.8168945
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Bottazzi ME, Zhan B, et al. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012;11(9):1043–1055. doi:10.1586/erv.12.8523151163
   PubMed Web of Science ®Google Scholar
• Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138(5):779.24434331
   PubMedGoogle Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114. doi:10.3389/fimmu.2013.0011423720661
   PubMed Web of Science ®Google Scholar
• Bertona D, Pujato N, Bontempi I, et al. Development and assessment of a new cage-like particle adjuvant. J Pharm Pharmacol. 2017;69(10):1293–1303. doi:10.1111/jphp.1276828664569
   PubMedGoogle Scholar
• Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine. 2005;23(17–18):2132–2135. doi:10.1016/j.vaccine.2005.01.05715755583
   PubMed Web of Science ®Google Scholar
• Santos FR, Ferraz DB, Daghastanli KR, Ramalho-Pinto FJ, Ciancaglini P. Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis. J Membr Biol. 2006;210(3):173–181. doi:10.1007/s00232-006-0005-616909340
   PubMedGoogle Scholar
• Mesa C, de León J, Rigley K, Fernández LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine. 2004;22(23–24):3045–3052. doi:10.1016/j.vaccine.2004.02.01015297054
   PubMed Web of Science ®Google Scholar
• Migliaccio V, Santos FR, Ciancaglini P, Ramalho-Pinto FJ. Use of proteoliposome as a vaccine against Trypanosoma cruzi in mice. Chem Phys Lipids. 2008;152(2):86–94. doi:10.1016/j.chemphyslip.2007.12.00318262496
   PubMedGoogle Scholar
• Engman D, Krause K, Blumin J, Kim K, Kirchhoff L, Donelson J. A novel flagellar Ca2+-binding protein in trypanosomes. J Biol Chem. 1989;264(31):18627–18631.2681200
   PubMed Web of Science ®Google Scholar
• Krautz G, Kissinger J, Krettli A. The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today. 2000;16(1):31–34.10637586
   PubMedGoogle Scholar
• Taibi A, Plumas-Marty B, Guevara-Espinoza A, et al. Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity. J Immunol. 1993;151(5):2676–2689.7689612
   PubMed Web of Science ®Google Scholar
• Taibi A, Espinoza AG, Ouaissi A. Trypanosoma cruzi: analysis of cellular and humoral response against a protective recombinant antigen during experimental Chagas’ disease. Immunol Lett. 1995;48(3):193–200.8867851
   PubMed Web of Science ®Google Scholar
• Godsel LM, Tibbetts RS, Olson CL, Chaudoir BM, Engman DM. Utility of recombinant flagellar calcium-binding protein for serodiagnosis of Trypanosoma cruzi infection. J Clin Microbiol. 1995;33(8):2082–2085.7559952
   PubMed Web of Science ®Google Scholar
• Guevara A, Taibi A, Alava J, Guderian R, Ouaissi A. Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease. Trans R Soc Trop Med Hyg. 1995;89(4):447–448. doi:10.1016/0035-9203(95)90052-77570896
   PubMedGoogle Scholar
• Vabulas RM, Pircher H, Lipford GB, Häcker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol. 2000;164(5):2372–2378. doi:10.4049/jimmunol.164.5.237210679072
   PubMedGoogle Scholar
• Speiser DE, Liénard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739–746. doi:10.1172/JCI2337315696196
   PubMed Web of Science ®Google Scholar
• Barry MA, Wang Q, Jones KM, et al. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother. 2016;12(4):976–987. doi:10.1080/21645515.2015.111934626890466
   PubMed Web of Science ®Google Scholar
• Hyland KV, Leon JS, Daniels MD, et al. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun. 2007;75(7):3641–3650. doi:10.1128/IAI.00423-0717485457
   PubMedGoogle Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109. doi:10.1161/CIRCULATIONAHA.106.62429617339569
   PubMed Web of Science ®Google Scholar
• Rocha M, Ribeiro A, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 2003;8(1):44–54. doi:10.2741/926
   Google Scholar
• Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 2001;31(5–6):550–554.11334941
   PubMed Web of Science ®Google Scholar
• Branquinho RT, Pound-Lana G, Milagre MM, et al. Increased body exposure to new anti-trypanosomal through nanoencapsulation. Sci Rep. 2017;7(1):8429. doi:10.1038/s41598-017-08469-x28814794
   PubMedGoogle Scholar
• Morilla MJ, Prieto MJ, Romero EL. Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components? Mem Inst Oswaldo Cruz. 2005;100(2):213–219. doi:10.1590/s0074-0276200500020001716021311
   PubMedGoogle Scholar
• Alderson NE. Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson. Interview by Barbara J Culliton. Health Aff (Millwood). 2008;27(4):w315–w317. doi:10.1377/hlthaff.27.4.w31518559355
   PubMedGoogle Scholar
• Clemons KV, Sobel RA, Martinez M, Correa-Oliveira R, Stevens DA. Lack of efficacy of liposomal amphotericin B against acute and chronic trypanosoma cruzi infection in mice. Am J Trop Med Hyg. 2017;97(4):1141–1146. doi:10.4269/ajtmh.16-097528820684
   PubMedGoogle Scholar
• de Souza W, Sant’Anna C, Cunha-e-Silva NL. Electron microscopy and cytochemistry analysis of the endocytic pathway of pathogenic protozoa. Prog Histochem Cytochem. 2009;44(2):67–124. doi:10.1016/j.proghi.2009.01.00119410686
   PubMedGoogle Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515. doi:10.1021/mp800051m18672949
   PubMed Web of Science ®Google Scholar
• Gentile F, Chiappini C, Fine D, et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech. 2008;41(10):2312–2318. doi:10.1016/j.jbiomech.2008.03.02118571181
   PubMed Web of Science ®Google Scholar
• Yoshihara E, Tachibana H, Nakae T. Trypanocidal activity of the stearylamine-bearing liposome in vitro. Life Sci. 1987;40(22):2153–2159. doi:10.1016/0024-3205(87)90005-13295443
   PubMed Web of Science ®Google Scholar